ADPT

Adaptive Biotechnologies Corporation Common Stock

13.46

USD

ADPT Earnings Reports

Positive Surprise Ratio

ADPT beat 22 of 27 last estimates.

81%

Next Report

Date of Next Report

Apr 29, 2026

Estimate for Q1 26 (Revenue/ EPS)

$61.92M

-$0.16

Implied change from Q4 25 (Revenue/ EPS)

-13.62%

+77.78%

Implied change from Q1 25 (Revenue/ EPS)

+18.07%

-20.00%

Adaptive Biotechnologies Corporation Common Stock earnings per share and revenue

On Feb 05, 2026, ADPT reported earnings of -0.09 USD per share (EPS) for Q4 25, beating the estimate of -0.18 USD, resulting in a 51.33% surprise. Revenue reached 71.68 million, compared to an expected 60.58 million, with a 18.33% difference. The market reacted with a -1.04% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 61.92 million USD, implying an increase of 77.78% EPS, and decrease of -13.62% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Trevi Therapeutics, Inc. Common Stock

Report Date

Mar 17, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.06

Surprise

+40.06%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Mar 16, 2026 For Q4 25

Estimate

-$0.53

Actual

-$0.50

Surprise

+7.29%

Alvotech Ordinary Shares

Report Date

Mar 18, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.37

Surprise

-706.10%

XOMA Royalty Corporation Common Stock

Report Date

Mar 18, 2026 For Q4 25

Estimate

-$0.15

Actual

$0.12

Surprise

+175.90%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Abeona Therapeutics Inc. Common Stock

Report Date

Mar 17, 2026 For Q4 25

Estimate

-$0.36

Actual

-$0.34

Surprise

+6.28%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Mar 18, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.07

Surprise

-1472.55%

Artiva Biotherapeutics, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.84

Actual

Surprise

Spruce Biosciences, Inc. Common Stock

Report Date

Apr 13, 2026 For Q4 25

Estimate

-$8.14

Actual

Surprise

Kyntra Bio, Inc. Common Stock

Report Date

Mar 16, 2026 For Q4 25

Estimate

-$3.96

Actual

-$3.61

Surprise

+8.90%

FAQ

What were Adaptive Biotechnologies Corporation Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Adaptive Biotechnologies Corporation Common Stock reported EPS of -$0.09, beating estimates by 51.33%, and revenue of $71.68M, 18.33% above expectations.

How did the market react to Adaptive Biotechnologies Corporation Common Stock's Q4 2025 earnings?

The stock price moved down -1.04%, changed from $18.26 before the earnings release to $18.07 the day after.

When is Adaptive Biotechnologies Corporation Common Stock expected to report next?

The next earning report is scheduled for Apr 29, 2026.

What are the forecasts for Adaptive Biotechnologies Corporation Common Stock's next earnings report?

Based on 10 analysts, Adaptive Biotechnologies Corporation Common Stock is expected to report EPS of -$0.16 and revenue of $61.92M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.